Uppsala, Sweden, February 13, 2024. Dicot Pharma publishes its year-end report for the financial year 2024 and for the fourth quarter. The report is available as an attached document and on www.dicotpharma.com. CEO Elin Trampe and CFO Björn Petersson will present the report in a webcast today at 10.00 CET, which can also be viewed afterwards - see link below.
Fourth quarter, October-December 2024
- Net sales amounts to SEK 0.0 million (0.0)
- Earnings after financial items amounts to SEK -20.8 million (-15.7)
- Earnings per share amounts to SEK -0.01 (-0.02)
- Cash at end of quarter SEK 113.4 million (47.3)
Financial year January-December 2024
- Net sales amounts to SEK 0.0 million (0.0)
- Earnings after financial items amounts to SEK -57.7 million (-44.2)
- Earnings per share amounts to SEK -0.05 (-0.08)
"With the excellent study results and the good financial situation, we can conclude that we are in a favorable position" says Elin Trampe, CEO.
Significant events during the quarter
- Dicot Pharma met the listing requirements for Nasdaq First North Growth Market Sweden in October, and first day of trading on the new marketplace was November 7.
- All relevant authorities gave Dicot Pharma approval in October to start the phase 2a clinical trial in Sweden, Denmark, and the Netherlands. In November, the first participants were dosed. The study started according to schedule, with the clinical part expected to last until mid-2025, followed by statistical analysis before results can be reported.
- The US Patent and Trademark Office issued in October Notice of Allowance for three patent applications, and in November and December, these additional patents were granted in the US for the erectile dysfunction drug candidate LIB-01. The patent family strengthens both product and method protection until 2042 and includes "Composition of Matter".
- In-depth clinical results from the phase 1 study were presented at the largest US conference in sexual medicine. The results were later published in The Journal of Sexual Medicine and has been selected for presentation at the European Society for Sexual Medicine's annual congress in February 2025.
Significant events after the quarter
- Early February, more than half of the 140 participants in the ongoing phase 2a study have been dosed. The recruitment rate is high and on schedule. The study is expected to be reported in mid-2025.
The year-end report will be presented by CEO Elin Trampe and CFO Björn Petersson in a webcast from Direkt Studio today at 10.00 CET via Webcast Dicot Pharma Year-end report 2024. The webcast can also be viewed afterwards via the same link.
For further information, please contact:
Elin Trampe, CEO Björn Petersson, CFO
Phone: +46 72 502 10 10 Phone: +46 76 109 0000
E-mail: elin.trampe@dicotpharma.com E-mail: bjorn.petersson@dicotpharma.com
About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01 into a potency drug to improve treatment of erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.
Dicot Pharma is listed on Nasdaq First North and has approximately 8,100 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.
This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.
This disclosure contains information that Dicot Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-02-2025 08:25 CET.
